Literature DB >> 20428197

ALK fusion genes in children with atypical myeloproliferative leukemia.

S Röttgers, M Gombert, A Teigler-Schlegel, K Busch, U Gamerdinger, R Slany, J Harbott, A Borkhardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20428197     DOI： 10.1038/leu.2010.18

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

Review 2.  JMML genomics and decisions.

Authors:  Charlotte M Niemeyer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.

Authors:  Y Maesako; A Okumura; K Takeoka; C Kishimori; K Izumi; Y Kamoda; F Iioka; T Akasaka; H Ohno
Journal:  Leukemia       Date:  2014-05-21       Impact factor: 11.528

4.  Therapeutically Targetable ALK Mutations in Leukemia.

Authors:  Julia E Maxson; Monika A Davare; Samuel B Luty; Christopher A Eide; Bill H Chang; Marc M Loriaux; Cristina E Tognon; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

5.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Ryan D Morin; Jinghui Zhang; Martin Hirst; Yongjun Zhao; Xiaoping Su; Shann-Ching Chen; Debbie Payne-Turner; Michelle L Churchman; Richard C Harvey; Xiang Chen; Corynn Kasap; Chunhua Yan; Jared Becksfort; Richard P Finney; David T Teachey; Shannon L Maude; Kane Tse; Richard Moore; Steven Jones; Karen Mungall; Inanc Birol; Michael N Edmonson; Ying Hu; Kenneth E Buetow; I-Ming Chen; William L Carroll; Lei Wei; Jing Ma; Maria Kleppe; Ross L Levine; Guillermo Garcia-Manero; Eric Larsen; Neil P Shah; Meenakshi Devidas; Gregory Reaman; Malcolm Smith; Steven W Paugh; William E Evans; Stephan A Grupp; Sima Jeha; Ching-Hon Pui; Daniela S Gerhard; James R Downing; Cheryl L Willman; Mignon Loh; Stephen P Hunger; Marco A Marra; Charles G Mullighan
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

Review 6.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 7.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

8.  inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.

Authors:  Yoshitomo Maesako; Kiyotaka Izumi; Satoshi Okamori; Kayo Takeoka; Chiyuki Kishimori; Atsuko Okumura; Gen Honjo; Takashi Akasaka; Hitoshi Ohno
Journal:  Int J Hematol       Date:  2013-12-04       Impact factor: 2.490

9.  Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Authors:  A Colomba; S Giuriato; E Dejean; K Thornber; G Delsol; H Tronchère; F Meggetto; B Payrastre; F Gaits-Iacovoni
Journal:  Blood Cancer J       Date:  2011-06-03       Impact factor: 11.037

Review 10.  Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

Authors:  Jian Li; Wei-hua Yin; Kengo Takeuchi; Hong Guan; Yu-hua Huang; John K C Chan
Journal:  Diagn Pathol       Date:  2013-09-13       Impact factor: 2.644
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.